IDH1 and cancer: In 2019, Lin et al. revealed the discovery of quinolinone derivativesas selective mutant IDH-1 inhibitors endowed with anti-cancer potential.64 Initially, 400 000 compounds were screenedthrough high-throughput screening (HTS) using the diaphorase assay.Among the screened compounds, quinolinone was the most suitable scaffold,and 68 was considered a hit compound for mIDH1 activity.Efforts were made to achieve potency, and a SAR was generated forhit 68 (shown in Figure 18).